Project Overview

P_ERP012611

Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome

Visibility: Public
Publication: Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome Link
 Journal: Gut Microbes
Source: NA
Sample Number: 175

Samples in this project
  

SampleID Type Habitat Year Sequence type MNS1 MAS2
S_ERP012611.ERR1051013 Gut Feces 2012 16S - -
S_ERP012611.ERR1051014 Gut Feces 2012 16S - -
S_ERP012611.ERR1051015 Gut Feces 2012 16S - -
S_ERP012611.ERR1051016 Gut Feces 2012 16S - -
S_ERP012611.ERR1051017 Gut Feces 2012 16S - -
S_ERP012611.ERR1051018 Gut Feces 2012 16S - -
S_ERP012611.ERR1051019 Gut Feces 2012 16S - -
S_ERP012611.ERR1051020 Gut Feces 2012 16S - -
S_ERP012611.ERR1051021 Gut Feces 2012 16S - -
S_ERP012611.ERR1051022 Gut Feces 2012 16S - -
S_ERP012611.ERR1051023 Gut Feces 2012 16S - -
S_ERP012611.ERR1051024 Gut Feces 2012 16S - -
S_ERP012611.ERR1051025 Gut Feces 2012 16S - -
S_ERP012611.ERR1051026 Gut Feces 2012 16S - -
S_ERP012611.ERR1051027 Gut Feces 2012 16S - -
S_ERP012611.ERR1051028 Gut Feces 2012 16S - -
S_ERP012611.ERR1051029 Gut Feces 2012 16S - -
S_ERP012611.ERR1051030 Gut Feces 2012 16S - -
S_ERP012611.ERR1051031 Gut Feces 2012 16S - -
S_ERP012611.ERR1051032 Gut Feces 2012 16S - -

1MNS (Microbiome Novelty Score): < 0.12: Non-novel; 0.12-0.2: Novel; > 0.2: Very novel; -: NA for samples before 2010

2MAS (Microbiome Attention Score): < 10: Low-attention; ≥ 10: High-attention; -: NA for samples before 2010